Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Genmab

Genmab
1999 FOUNDED
PUBLIC STATUS
401-500 EMPLOYEES
GEN STOCK SYMBOL
2 INVESTMENTS
$183.12 SHARE PRICE (As of Monday Closing)
Description

Genmab is a cancer drug developer, best known for its antibody technology platforms, DuoBody and HexaBody, and its promising first-in-class multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company also has several pipeline candidates targeting other oncologic indications and autoimmune diseases.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
CSE
Primary Office
  • Kalvebod Brygge 43
  • 1560 Copenhagen
  • Denmark

+45 70 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Genmab’s full profile, request a free trial.

Genmab Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$119.85 - $186.17 $11.3B $181.68 $3.41 143K 61.5M

Genmab Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 9,722,539 9,166,493 9,525,445 9,521,863
Revenue 455,554 478,862 358,556 269,745
EBITDA 197,042 259,138 165,959 169,144
Net Income 208,874 233,031 167,278 176,314
Total Assets 1,313,177 1,296,141 1,064,064 741,210
Total Debt 29,982
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Genmab Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Genmab‘s full profile, request access.

Request full access to PitchBook

Genmab Competitors (45)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exelixis Formerly VC-backed Alameda, CA 000 00000 0&0
000000 Formerly VC-backed Cambridge, MA 0000 000.00 00000000000 000.00
0000000 00000000 Formerly VC-backed Bothell, WA 0000 00000 000000000 00000
00000 & 00. Corporation Kenilworth, NJ 00000
000000000 00000000 Formerly VC-backed Zurich, Switzerland 000 00000 00000000000 00000
To view this company’s complete list of competitors, request access »

Genmab Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 0000000 (00000 19-Mar-2015 000000000 00000 00 00.000 Drug Discovery 000 000 00 000000 00.0
Paradigm Therapeutics 09-Dec-2002 Early Stage VC 0000 Drug Discovery
To view this company’s complete investment and acquisition history, request access »

Genmab Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000000 000000000 09-Dec-2002 00000 00000 00 0000 Completed
  • 4 buyers
To view this company’s complete exits history, request access »

Genmab Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Genmab‘s full profile, request access.

Request full access to PitchBook

Genmab Executive Team (9)

Name Title Board
Seat
Contact
Info
Jan van de Winkel Ph.D Founder, President & Chief Executive Officer
David Eatwell Chief Financial Officer & Executive Vice President
Judith Klimovsky Chief Development Officer & Executive Vice President
Martine Vugt Chief of Staff
Michael Bauer Ph.D Senior Vice President & Head of Operations Research & Development

1 Former Executive

You’re viewing 5 of 9 executives. Get the full list »

Genmab Board Members (13)

Name Representing Role Since Contact
Info
Anders Gersel Pedersen Self Board Member 000 0000
Daniel Bruno Genmab Board Member 000 0000
Mats Pettersson Genmab Chairman 000 0000
Mijke Zachariasse Ph.D Genmab Board Member 000 0000
Paolo Paoletti MD Self Board Member & Chairman of the Scientific Committee; Member of the Compensation Committee 000 0000

5 Former Board Members

You’re viewing 5 of 13 board members. Get the full list »